» Articles » PMID: 18353774

AMP-activated Protein Kinase and P38 MAPK Activate O-GlcNAcylation of Neuronal Proteins During Glucose Deprivation

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2008 Mar 21
PMID 18353774
Citations 142
Authors
Affiliations
Soon will be listed here.
Abstract

We have demonstrated previously that a wide array of stress signals induces O-GlcNAc transferase (OGT) expression and increases O-GlcNAcylation of many intracellular proteins, a response that is critical for cell survival. Here, we describe a mechanism by which glucose deprivation induces OGT expression and activity in Neuro-2a neuroblastoma cells. Glucose deprivation increases OGT mRNA and protein expression in an AMP-activated protein kinase-dependent manner, whereas OGT enzymatic activity is regulated in a p38 MAPK-dependent manner. OGT is not phosphorylated by p38, but rather it interacts directly with p38 through its C terminus; this interaction increases with p38 activation during glucose deprivation. Surprisingly, the catalytic activity of OGT, as measured toward peptide substrates, is not altered by glucose deprivation. Instead, p38 regulates OGT activity within the cell by recruiting it to specific targets, including neurofilament H. Neurofilament H is O-GlcNAcylated during glucose deprivation in a p38-dependent manner. Interestingly, neurofilament H solubility is increased by glucose deprivation in an O-GlcNAc-dependent manner, suggesting that O-GlcNAcylation of neurofilament H regulates its disassembly from filaments. Not only do these data help to reveal how OGT is regulated by stress, but these findings also describe a possible mechanism by which defective brain glucose metabolism, as found in aging and ischemia, may directly affect axonal structure.

Citing Articles

The role of O-GlcNAcylation in bone metabolic diseases.

Yang Y, Zhou X, Deng H, Chen L, Zhang X, Wu S Front Physiol. 2024; 15:1416967.

PMID: 38915778 PMC: 11194333. DOI: 10.3389/fphys.2024.1416967.


O-glycosylation in viruses: A sweet tango.

Ming A, Zhao J, Liu Y, Wang Y, Wang X, Li J mLife. 2024; 3(1):57-73.

PMID: 38827513 PMC: 11139210. DOI: 10.1002/mlf2.12105.


O-GlcNAcylation in ischemic diseases.

Shi R, He T, Lin M, Xu J, Gu J, Xu H Front Pharmacol. 2024; 15:1377235.

PMID: 38783961 PMC: 11113977. DOI: 10.3389/fphar.2024.1377235.


Regulation of protein O-GlcNAcylation by circadian, metabolic, and cellular signals.

Liu X, Cai Y, Chiu J J Biol Chem. 2023; 300(2):105616.

PMID: 38159854 PMC: 10810748. DOI: 10.1016/j.jbc.2023.105616.


Tools for investigating O-GlcNAc in signaling and other fundamental biological pathways.

Nelson Z, Leonard G, Fehl C J Biol Chem. 2023; 300(2):105615.

PMID: 38159850 PMC: 10831167. DOI: 10.1016/j.jbc.2023.105615.


References
1.
Liu F, Iqbal K, Grundke-Iqbal I, Hart G, Gong C . O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101(29):10804-9. PMC: 490015. DOI: 10.1073/pnas.0400348101. View

2.
Fulop N, Zhang Z, Marchase R, Chatham J . Glucosamine cardioprotection in perfused rat hearts associated with increased O-linked N-acetylglucosamine protein modification and altered p38 activation. Am J Physiol Heart Circ Physiol. 2007; 292(5):H2227-36. PMC: 2850194. DOI: 10.1152/ajpheart.01091.2006. View

3.
Zachara N, Hart G . Cell signaling, the essential role of O-GlcNAc!. Biochim Biophys Acta. 2006; 1761(5-6):599-617. DOI: 10.1016/j.bbalip.2006.04.007. View

4.
Hoyer S . Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004; 490(1-3):115-25. DOI: 10.1016/j.ejphar.2004.02.049. View

5.
Cuenda A, Rouse J, Doza Y, Meier R, Cohen P, Gallagher T . SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995; 364(2):229-33. DOI: 10.1016/0014-5793(95)00357-f. View